Cleveland, Ohio – July 7, 2026 – SPR announced the publication of long-term data in the journal Pain and Therapy from a cross-sectional follow-up survey of real-world patients (n=602) with chronic low back pain who had previously responded to treatment with the SPRINT Peripheral Nerve Stimulation (PNS) System. Overall, 79 percent of survey participants avoided subsequent interventions including radiofrequency ablation (RFA), permanent neurostimulator implant, and low back surgery through the period of follow-up which ranged from six months to over five years.
The study followed up with patients who had chronic low back pain and previously responded to SPRINT PNS at end of treatment, evaluating long-term outcomes and the use or avoidance of subsequent pain interventions. The findings highlight the potential for patients with low back pain who initially respond to the 60-day SPRINT PNS treatment to maintain long-term reductions in pain leading to improvements in other domains of patient health including quality of life, physical function, mood, and/or sleep. Safety outcomes were not specifically analyzed in the long-term follow-up survey.
Key findings included:
Among patients who had no prior permanent neurostimulator implant and reported they were actively trying to avoid one, 92 percent (309/336) were successful in avoiding a permanent implant through follow-up.
Of those patients with no prior low back surgery who reported they were actively trying to avoid surgery, 95 percent (353/370) were successful in avoiding low back surgery at the time of follow-up.
- According to the publication, “Consistent with prior studies, the results support the role of percutaneous 60-day PNS as a minimally invasive, short-term treatment option with potential to provide durable clinical benefits for up to 5+ years, with many patients reporting avoidance of subsequent interventions.”
The full publication is available in Pain and Therapy here.
Dr. Samir Sheth, board-certified anesthesiologist, interventional pain specialist, lead author, and SPR consultant, noted, “For patients who respond to SPRINT PNS, these data suggest they stand a strong chance of experiencing long-term benefits, avoiding additional interventions down the road. The multi-dimensional nature of the improvements we observed, spanning pain, quality of life, function, mood, and sleep, reflects how meaningfully this treatment can impact patients’ lives.”
Maria Bennett, President, CEO, and Founder of SPR noted, “The potential for a patient seeking to avoid further interventions and more invasive care to find relief through a 60-day treatment is significant. These outcomes with sustained relief, some over five years from treatment, are consistent with previous studies and reinforces our belief that SPRINT PNS can be used early in the treatment continuum.”
SPR Contact
Dave Folkens
Public Relations
[email protected]
612.978.6547